首页> 外文期刊>Vaccine >Safety and efficacy of E-coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori
【24h】

Safety and efficacy of E-coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori

机译:大肠杆菌肠毒素佐剂在基于脲酶的幽门螺杆菌直肠免疫中的安全性和有效性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Low dose E. coli heat-labile enterotoxin (LT), delivered orally or enterically, has been used as an adjuvant for Helicobacter pylori (H. pylori) urease in healthy adults. In this study we aim to test the safety and adjuvant efficacy of LT delivered rectally together with recombinant H. pylori urease. Eighteen healthy adults without present or past H. pylori infection were enrolled in a double blind, randomized, ascending dose study to receive either urease (60 mg), or urease (60 mg) + LT (5 or 25 mug). The immunization preparation was administered per rectum on days 0, 14 and 28. Serum, stool and saliva anti-urease and anti-LT IgG and IgA antibodies (Abs) were measured and urease-specific and LT-specific antigen secreting cells (ASCs) were counted in peripheral blood at baseline and 7 (ASC counts) or 14 days (antibody levels) after each dosing. Peripheral blood lymphoproliferation assays were also performed at baseline and at the end of the study.
机译:口服或肠溶的低剂量大肠杆菌不耐热肠毒素(LT)已被用作健康成年人中幽门螺杆菌(H. pylori)脲酶的佐剂。在这项研究中,我们旨在测试与重组幽门螺杆菌脲酶一起直肠递送的LT的安全性和佐剂功效。 18名没有现在或过去的幽门螺杆菌感染的健康成人参加了一项双盲,随机,递增剂量研究,接受尿素酶(60 mg)或尿素酶(60 mg)+ LT(5或25杯)。在第0、14和28天对每个直肠施用免疫制剂。测量血清,粪便和唾液抗尿素酶以及抗LT IgG和IgA抗体(Abs),并测定脲酶特异性和LT特异性抗原分泌细胞(ASC)在每次给药后的第7天(ASC计数)或14天(抗体水平)对外周血进行计数。在基线和研究结束时也进行了外周血淋巴细胞增殖测定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号